Verekitug for Asthma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores the long-term safety and effectiveness of a new treatment called verekitug for people with asthma. Participants will receive injections of verekitug or a placebo every few months. The trial is designed for those who completed a previous study called VALIANT and wish to continue their treatment journey. It suits individuals who have managed asthma but seek more control over their symptoms. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Do I have to stop taking my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that verekitug is generally safe and well-tolerated. In earlier studies, researchers tested verekitug at different doses, and participants handled it well, with no major safety issues or serious side effects. These results are encouraging and support further research on verekitug for asthma.12345
Why are researchers excited about this trial's treatments?
Verekitug is unique because it offers a new way to tackle asthma with its distinct dosing schedule and delivery method. Unlike most asthma treatments that require daily administration, Verekitug is administered via subcutaneous injections every 12 or 24 weeks. This less frequent dosing could significantly improve convenience and adherence for patients. Additionally, researchers are intrigued by its potential to maintain asthma control over extended periods, which might be a game-changer compared to conventional inhalers or oral medications.
What evidence suggests that verekitug might be an effective treatment for asthma?
Research has shown that verekitug can significantly reduce inflammation in people with asthma. Studies have found that it lowers a marker of airway inflammation called fractional exhaled nitric oxide (FeNO) by more than 50%. It also quickly and greatly reduces blood eosinophils, which are white blood cells often elevated in people with asthma. These findings suggest that verekitug could help reduce asthma symptoms by targeting inflammation. The drug did not cause serious side effects, indicating it was well tolerated. Overall, these results are promising for those with severe asthma. Participants in this trial will receive either 100 mg of verekitug every 12 weeks or 400 mg every 24 weeks, alongside placebo injections, to further evaluate its effectiveness and safety.13678
Who Is on the Research Team?
James C Lee, MD
Principal Investigator
Upstream Bio
Are You a Good Fit for This Trial?
This trial is for adults who have severe asthma and completed the VALIANT study. Participants must consent to long-term follow-up and agree to use contraception according to local regulations.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive verekitug (UPB-101) and placebo injections every 12 or 24 weeks for up to 48 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Verekitug
Find a Clinic Near You
Who Is Running the Clinical Trial?
Upstream Bio Inc.
Lead Sponsor